Lisata Therapeutics Net Worth
Lisata Therapeutics Net Worth Breakdown | LSTA |
Lisata Therapeutics Net Worth Analysis
Lisata Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lisata Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lisata Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lisata Therapeutics' net worth analysis. One common approach is to calculate Lisata Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lisata Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lisata Therapeutics' net worth. This approach calculates the present value of Lisata Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lisata Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lisata Therapeutics' net worth. This involves comparing Lisata Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lisata Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Lisata Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lisata Therapeutics' net worth research are outlined below:
| Lisata Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Junshi Biosciences Announces Toripalimabs Approval in Australia |
Lisata Therapeutics Quarterly Good Will |
|
Lisata Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lisata Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lisata Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Lisata Therapeutics Target Price Consensus
Lisata target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Lisata Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Lisata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Lisata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Lisata Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationLisata Therapeutics Target Price Projection
Lisata Therapeutics' current and average target prices are 2.68 and 14.00, respectively. The current price of Lisata Therapeutics is the price at which Lisata Therapeutics is currently trading. On the other hand, Lisata Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Lisata Therapeutics Market Quote on 22nd of January 2025
Target Price
Analyst Consensus On Lisata Therapeutics Target Price
Know Lisata Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lisata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lisata Therapeutics backward and forwards among themselves. Lisata Therapeutics' institutional investor refers to the entity that pools money to purchase Lisata Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 1.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.5 K | Ubs Group Ag | 2024-09-30 | 125 | Royal Bank Of Canada | 2024-09-30 | 52.0 | Jpmorgan Chase & Co | 2024-09-30 | 15.0 | Barclays Plc | 2024-09-30 | 7.0 | Wells Fargo & Co | 2024-09-30 | 1.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 1.0 | Steward Partners Investment Advisory, Llc | 2024-09-30 | 0.0 | Bml Capital Management Llc | 2024-09-30 | 284.7 K | Vanguard Group Inc | 2024-09-30 | 186.4 K |
Follow Lisata Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.74 M.Market Cap |
|
Project Lisata Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.48) | (0.51) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (0.50) | (0.52) |
When accessing Lisata Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lisata Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lisata Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Lisata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lisata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lisata Therapeutics' management manipulating its earnings.
Evaluate Lisata Therapeutics' management efficiency
Lisata Therapeutics has return on total asset (ROA) of (0.2872) % which means that it has lost $0.2872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4403) %, meaning that it created substantial loss on money invested by shareholders. Lisata Therapeutics' management efficiency ratios could be used to measure how well Lisata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 22, 2025, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.51. At present, Lisata Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 65.1 M, whereas Total Assets are forecasted to decline to about 43.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.34 | 5.61 | |
| Tangible Book Value Per Share | 5.31 | 5.58 | |
| Enterprise Value Over EBITDA | 0.01 | 0.01 | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | 0.01 | 0.01 | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | 25.9 M | 36.1 M |
Understanding the operational decisions made by Lisata Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lisata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lisata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lisata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
James Nisco over six months ago Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 | ||
James Nisco over six months ago Disposition of 3000 shares by James Nisco of Lisata Therapeutics at 3.0 subject to Rule 16b-3 | ||
James Nisco over six months ago Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 | ||
Buck Kristen K over six months ago Disposition of 50103 shares by Buck Kristen K of Lisata Therapeutics at 1.28 subject to Rule 16b-3 | ||
Wei Eric 1 over a year ago Lisata Therapeutics exotic insider transaction detected |
Lisata Therapeutics Corporate Filings
F4 | 13th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of August 2024 Other Reports | ViewVerify | |
| 15th of July 2024 Other Reports | ViewVerify |
Lisata Therapeutics Earnings Estimation Breakdown
The calculation of Lisata Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Lisata Therapeutics is estimated to be -0.654175 with the future projection ranging from a low of -0.67 to a high of -0.6325. Please be aware that this consensus of annual earnings estimates for Lisata Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.67 Lowest | Expected EPS | -0.63 Highest |
Lisata Therapeutics Earnings Projection Consensus
Suppose the current estimates of Lisata Therapeutics' value are higher than the current market price of the Lisata Therapeutics stock. In this case, investors may conclude that Lisata Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Lisata Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 2 | 65.5% | -0.59 | -0.654175 | -2.51 |
Lisata Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Lisata Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Lisata Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Lisata Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Lisata Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Lisata Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Lisata Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Lisata Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Lisata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-01 | 2024-09-30 | -0.77 | -0.59 | 0.18 | 23 | ||
2024-08-12 | 2024-06-30 | -0.76 | -0.61 | 0.15 | 19 | ||
2024-05-09 | 2024-03-31 | -0.72 | -0.65 | 0.07 | 9 | ||
2024-02-29 | 2023-12-31 | -0.89 | -0.66 | 0.23 | 25 | ||
2023-11-02 | 2023-09-30 | -0.93 | -0.65 | 0.28 | 30 | ||
2023-08-14 | 2023-06-30 | -0.7 | -0.5 | 0.2 | 28 | ||
2023-05-09 | 2023-03-31 | -0.81 | -0.77 | 0.04 | 4 | ||
2023-03-30 | 2022-12-31 | -1.01 | -0.76 | 0.25 | 24 | ||
2022-11-10 | 2022-09-30 | -0.9 | -7.88 | -6.98 | 775 | ||
2022-08-04 | 2022-06-30 | -1.45 | -1.65 | -0.2 | 13 | ||
2022-05-05 | 2022-03-31 | -1.45 | -1.05 | 0.4 | 27 | ||
2022-03-22 | 2021-12-31 | -2.17 | -1.65 | 0.52 | 23 | ||
2021-11-04 | 2021-09-30 | -2.25 | -1.8 | 0.45 | 20 | ||
2021-08-05 | 2021-06-30 | -2.17 | -1.5 | 0.67 | 30 | ||
2021-05-06 | 2021-03-31 | -1.27 | -2.85 | -1.58 | 124 | ||
2021-02-25 | 2020-12-31 | -3.8 | -4.2 | -0.4 | 10 | ||
2020-11-05 | 2020-09-30 | -4.35 | -4.35 | 0.0 | 0 | ||
2020-08-13 | 2020-06-30 | -5.81 | 7.5 | 13.31 | 229 | ||
2020-05-07 | 2020-03-31 | -4.35 | -5.7 | -1.35 | 31 | ||
2020-03-05 | 2019-12-31 | -5.17 | -7.05 | -1.88 | 36 | ||
2019-11-06 | 2019-09-30 | -6.45 | -7.05 | -0.6 | 9 | ||
2019-08-08 | 2019-06-30 | -6.67 | -7.35 | -0.68 | 10 | ||
2019-05-09 | 2019-03-31 | -6.37 | -6.6 | -0.23 | 3 | ||
2019-03-14 | 2018-12-31 | -6.6 | -5.4 | 1.2 | 18 | ||
2018-11-08 | 2018-09-30 | -8.4 | -5.4 | 3.0 | 35 | ||
2018-08-09 | 2018-06-30 | -9.6 | -8.55 | 1.05 | 10 | ||
2018-05-10 | 2018-03-31 | -10.05 | -7.8 | 2.25 | 22 | ||
2018-03-22 | 2017-12-31 | -10.42 | -6.15 | 4.27 | 40 | ||
2017-11-09 | 2017-09-30 | -11.62 | -5.7 | 5.92 | 50 | ||
2017-08-10 | 2017-06-30 | -14.4 | -3.3 | 11.1 | 77 | ||
2017-05-15 | 2017-03-31 | -10.8 | -16.8 | -6.0 | 55 | ||
2017-03-17 | 2016-12-31 | -11.92 | -10.95 | 0.97 | 8 | ||
2016-11-07 | 2016-09-30 | -23.2 | -16.35 | 6.85 | 29 | ||
2016-08-09 | 2016-06-30 | -25.95 | -19.95 | 6.0 | 23 | ||
2016-05-05 | 2016-03-31 | -27 | -31.5 | -4.5 | 16 | ||
2016-03-15 | 2015-12-31 | -41.25 | -88.5 | -47.25 | 114 | ||
2015-11-05 | 2015-09-30 | -51.5 | -31.5 | 20.0 | 38 | ||
2015-08-06 | 2015-06-30 | -46.24 | -25.5 | 20.74 | 44 | ||
2015-05-05 | 2015-03-31 | -54 | -76.5 | -22.5 | 41 | ||
2015-03-02 | 2014-12-31 | -62.7 | -48.0 | 14.7 | 23 | ||
2014-10-30 | 2014-09-30 | -51.3 | -72.0 | -20.7 | 40 | ||
2014-08-07 | 2014-06-30 | -44.7 | -60.0 | -15.3 | 34 | ||
2014-05-08 | 2014-03-31 | -59.25 | -73.5 | -14.25 | 24 | ||
2014-03-13 | 2013-12-31 | -53.5 | -70.5 | -17.0 | 31 | ||
2013-11-07 | 2013-09-30 | -63.37 | -67.5 | -4.13 | 6 | ||
2013-08-08 | 2013-06-30 | -61.5 | -69.0 | -7.5 | 12 | ||
2013-05-09 | 2013-03-31 | -67.5 | -75.0 | -7.5 | 11 | ||
2013-03-11 | 2012-12-31 | -80 | -150.0 | -70.0 | 87 | ||
2012-11-14 | 2012-09-30 | -75 | -90.0 | -15.0 | 20 | ||
2012-08-14 | 2012-06-30 | -120 | -75.0 | 45.0 | 37 | ||
2012-05-11 | 2012-03-31 | -120 | -120.0 | 0.0 | 0 | ||
2012-03-20 | 2011-12-31 | -101.25 | -285.0 | -183.75 | 181 | ||
2011-11-11 | 2011-09-30 | -165 | -120.0 | 45.0 | 27 | ||
2011-08-12 | 2011-06-30 | -141 | -195.0 | -54.0 | 38 | ||
2011-05-17 | 2011-03-31 | -116.25 | -210.0 | -93.75 | 80 | ||
2010-11-12 | 2010-09-30 | -120 | -195.0 | -75.0 | 62 | ||
2010-08-16 | 2010-06-30 | -95 | -165.0 | -70.0 | 73 | ||
2010-05-17 | 2010-03-31 | -75 | -180.0 | -105.0 | 140 |
Lisata Therapeutics Corporate Management
| Kristen MD | Executive Officer | Profile | |
| Gail Holler | Vice Resources | Profile | |
| James Nisco | Treasurer, Finance | Profile | |
| Tariq Imam | Vice Counsel | Profile | |
| Ian MBA | Inc NeoStem | Profile | |
| Gregory Berkin | Chief Officer | Profile | |
| John Menditto | Vice Communications | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.